Close Menu

BARCELONA – Atezolizumab (Roche's Tencentriq) improved overall survival in non-small cell lung cancer (NSCLC) patients with high PD-L1 expression when compared to chemotherapy, an interim analysis of the IMpower110 study has found.

David Spigel, chief scientific officer and lung cancer program director at Sarah Cannon Research Institute, presented the data at the annual meeting of the European Society for Medical Oncology in Barcelona today. He said the interim analysis showed that atezolizumab "represents a promising first-line treatment" for this patient population.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.


In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.